

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Phillips, John A.		POSITION TITLE Professor of Pediatrics, Biochemistry and Medicine	
eRA COMMONS USER NAME (credential, e.g., agency login) phillija			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of North Carolina at Chapel Hill Bowman Gray School of Medicine	None M.D.	1962-1965 1965-1969	Chemistry Medicine

A. Positions and Honors

Positions and Employment

1969-71 Intern and Jr. Resident Pediatrics, Children's Hospital Medical Center, Boston, MA
 1971-73 Lt. Comdr., USNR (MC) Naval Regional Medical Center, Jacksonville, FL
 1973-75 Sr. and Chief Resident, Pediatrics, Children's Hospital Medical Center, Boston, MA
 1975 Sidney Farber Award, Children's Hospital Medical Center, Boston, MA
 1975-77 Research Fellow in Pediatric Genetics, Johns Hopkins Univ. Schl of Medicine, Baltimore, MD
 1981- Member, Society for Pediatric Research
 1978-82 Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
 1982-84 Associate Professor of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD
 1984- Professor of Pediatrics and Biochemistry; Director, Division of Genetics, Vanderbilt University School of Medicine, Nashville, TN
 1984 E. Mead Johnson Award for Research in Pediatric Research
 1984-88 Member, Board of Scientific Counselors, NICHD
 1985- Member, American Society for Clinical Investigation
 1992- David T. Karzon Professor of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN
 1994-00 Member, Board of Directors, American College of Medical Genetics
 1994-08 Elected by Peers for inclusion in Best Doctors in America
 1999- Member Executive Board, Vanderbilt Program in Human Genetics
 1999- Adjunct Professor of Microbiology, Meharry Medical College, Nashville, TN
 2001-06 Director, Genetics Training Program (T32, GM62758)
 2001-07 GCRC Director of Genetics, Vanderbilt General Clinical Research Center
 2002 Harvie Branscomb Distinguished Professor Award, Vanderbilt University School of Medicine
 2002-08 Selected as one of "America's Top Pediatricians"
 2003-08 Co-Investigator and CORE Lab Director PPH PPG (HL072058)
 2006-08 Course Director, Genetics (IDIS5040) Course, Vanderbilt University School of Medicine
 2005- Co-Director, American College Medical Genetics Board Review Course

B. Selected peer-reviewed publications (in chronological order)

Scott, AF, Phillips, JA III and Migeon, BR: DNA restriction endonuclease analysis for the localization of the human delta and beta globin genes on chromosome 11. Proc. Natl. Acad. Sci. USA 76:4563-4565, 1979.
 Phillips, JA III, Hjelle, BL, Seeburg, PH and Zachmann, M: A molecular basis for familial isolated growth hormone deficiency. Proc. Natl. Acad. Sci. USA 78:6372-6375, 1981.
 Stokes, DC, Phillips, JA III, Leonard, CO, Dorst, JP, Kopits, SE, Trojak, JE and Brown, DL: Respiratory complications of achondroplasia. J. Pediat. 102:534-541, 1983.
 Boehm, CD, Antonarakis, SE, Phillips, JA III, Stetten, G, and Kazazian, HH Jr: Prenatal diagnosis using DNA polymorphisms: Report on 95 pregnancies at risk for sickle-cell disease or β -thalassemia. New Engl. J. Med. 308:1054-1058, 1983.

- Antonarakis, SE, Phillips, JA III, Mallonee, RL, Kazazian, HH Jr, Waber, PG, Kronenberg, HM, Ullrich, A and Myers, DA: β -globin locus is linked to the parathyroid hormone (PTH) locus and lies between the insulin and PTH loci. *Proc. Natl. Acad. Sci. USA* 80:6615-6619, 1983.
- Chakravarti, A, Phillips, JA III, Mellits, KH, Buetow, KH and Seeburg, PH: Patterns of polymorphism and linkage disequilibrium in the human growth hormone cluster suggest multiple duplication events. *Proc. Natl. Acad. Sci. USA* 81:6085-6089, 1984.
- Folstein, SE, Phillips, JA III, Meyers, DA, Chase, GA, Waber, PG, Kazazian, HH, Conneally, PM, Hobbs, W and Gusella, J.: Huntington's Disease: Two families with differing clinical features show linkage to the G8 probe. *Science* 229:776-779, 1985.
- Vnencak-Jones, CL, Phillips, JA, III, Chen, EY, and Seeburg, PH: Molecular basis of human growth hormone gene deletions. *Proc. Natl. Acad. Sci (USA)* 85:5615-5619, 1988.
- Vnencak-Jones, CL and Phillips, JA III: Non Alu sequences constitute hot spots for human growth hormone gene deletions. *Science* 250:1745-1748, 1990.
- Campbell, PW III, Phillips, JA III, Krishnamani, MRS, Maness, KJ and Hazinski, TA: Cystic Fibrosis: Relationship between clinical status and F508. *J. Peds.* 118:239-241, 1991.
- Campbell, PW III, Parker, RA, Roberts, BT, Krishnamani, MRS and Phillips, JA III: Association of poor clinical status and heavy exposure to tobacco smoke in cystic fibrosis patients homozygous for the F508 deletion. *J. Peds.* 120: 261-264, 1992.
- The cystic fibrosis genotype-phenotype consortium: Correlation between genotype and phenotype in cystic fibrosis: Analysis of seven common mutations. *N. Engl. J. Med.* 329:1308-1313, 1993.
- Cogan, JD, Ramel, B, Lehto, M, Phillips, JA III, Prince, M, Blizzard, M, deRavel, TJL, Brammert, M and Groop, L: A recurring dominant-negative mutation causes autosomal dominant growth hormone deficiency. *J. Clin. Endocrinol. & Metab.* 80:3591-3595, 1995.
- Clayton, EW, Hannig, VL, Pfothauer, JP, Parker, RA, Campbell, PW III and Phillips, JA III: Teaching about cystic fibrosis carrier screening using written and video information. *Am. J. Hum. Genet.* 57:171-181, 1995.
- Campbell, PW III, Phillips, JA III, Heidecker, GJ, Krishnamani, MRS, Zahorchak, R and Stull, TL: Detection of *Pseudomonas (Burkholderia) cepacia* using species-specific PCR. *Pediatric Pulmonology* 20:44-49, 1995.
- Clayton, EW, Hannig, VL, Pfothauer, JP, Parker, RA, Campbell, PW III & Phillips, JA III: Lack of interest by nonpregnant couples in population based CF carrier screening. *Am. J. Hum. Genet.* 58:617-627, 1996.
- Nichols, WC, Koller, DL, Slovis, B, Foroud, T, Terry, VH, Arnold, ND, Siemieniak, DR, Wheeler, L, Phillips, JA III, Newman, JH, Conneally, PM, Ginsburg, D and Loyd, JE: Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. *Nature Genetics* 15:277-280, 1997.
- Cogan, JD, Prince, MA, Lekhakula, S, Bunday, S, Futrakul, A, McCarthy, EMS and Phillips, JA III: A novel mechanism of aberrant pre-mRNA splicing in humans. *Hum. Molec. Genetics* 6:909-912, 1997.
- Wu, W, Cogan, JD, Pfaffle, RW, Dasen, JS, Frisch, H, O'Connell, SM, Flynn, SE, Brown, MR, Mullis, PE, Parks, JS, Phillips, JA III and Rosenfeld, MG: Mutations in PROP1 cause familial combined pituitary hormone deficiency. *Nature Genetics* 18:147-149, 1998.
- McCarthy, EMS and Phillips, JA III: Characterization of an intron splice enhancer that regulates alternative splicing of GH pre-mRNA. *Human Molec. Genetics* 7:1491-1496, 1998.
- Salvatori, R, Gondo, RG, de Aguirar Oliveira, MH, Phillips, JA III, Souza, AH, Hayashida, CY, Toledo, SP, Conceicao, MM, Prince, M, Baumann, G and Levine, MA: Familial isolated growth hormone deficiency due to a novel mutation in the GHRHR. *J. Clin. Endo. Metab.* 84:917-923, 1999.
- The International PPH Consortium. Lane, KB, Machado, Pauciulo, MW, Thomson, JR, Philips JA III, Loyd, JE, Nichols, WC, and Trembath, RC: Heterozygous Germline mutations in BMPR-II are the cause of Familial Primary Pulmonary Hypertension. *Nature Genetics* 26:81-84, 2000.
- Cogan, JD and Phillips, JA III: Inherited defects in growth hormone synthesis and action. In: *The Metabolic and Molecular Bases of Inherited Disease*, Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. (eds), 8th edition, McGraw-Hill, pp 4159-4180, 2000.
- Williams, SM, Addy, JH, Phillips, JA III, Dai, M, Kpodonu, J, Afful, J, Jackson, H, Joseph, K, Eason, F, Murray, MM, Epperson, P, Aduonum, A, Wong, L-J, Jose, PA and Felder, RA: Combinations of variations in multiple genes are associated with hypertension. *Hypertension* 36:2-6, 2000.
- Newman, JH, Wheeler, L, Lane, KB, Loyd, E, Gaddipati, R, Phillips, JA III and Loyd, JE: Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. *N. Engl. J. Med.* 345:319-324, 2001.
- Dawson, ET and Phillips, JA III: Method for determining polynucleotide sequence variations. United States Patent # 6, 322,988 B1, Nov 27, 2001.
- Moseley, CT, Mullis, PE, Prince, MA and Phillips, JA III: An exon splice enhancer mutation causes autosomal dominant growth hormone deficiency. *J. Clin. Endocrinol. Metab.* 87: 847-852, 2002.

- Thomas, AQ, Lane, K, Phillips, JA III, Prince, M., Markin, C, Gaddipati, R, Marney, A, Johnson, J, Haines, J, Stahlman, M and Loyd, JE: Heterozygosity for a surfactant protein C mutation causes familial usual interstitial pneumonitis in adults and cellular interstitial pneumonitis in children. *Am J Respir Crit Care Med* 165: 1322-1328, 2002.
- Runo, JR, Vnencak-Jones, CL, Prince, M, Loyd, JE, Wheeler, L, Robbins, IM, Lane, KB, Newman, JH, Johnson, J, Nichols, WC and Phillips, JA III: Pulmonary veno-occlusive disease caused by an inherited mutation in the bone morphogenetic protein receptor2. *Am J Respir Crit Care Med* 167: 889-894, 2003.
- McGuinness, L, Magoulas, C, Sesay, AK, Mathers, K, Carmignac, D, Manneville, J-B, Christian, H, Phillips, J.A. III and Robinson, ICAF: Autosomal dominant growth hormone deficiency disrupts secretory vesicles *in vitro* and *in vivo* in transgenic mice. *Endocrinol* 144: 720-731, 2003.
- Ryther, RCC, McGuinness, LM, Phillips, JA III, Moseley, CT, Magoulas, CB, Robinson, ICAF and Patton, JG: Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II. *Hum Genet* 113:140-148, 2003.
- McGuinness, L, Magoulas, C, Sesay, AK, Mathers, K, Carmignac, D, Manneville, J-B, Christian, H, Phillips, JA III and Robinson, ICAF: Autosomal dominant growth hormone deficiency disrupts secretory vesicles *in vitro* and *in vivo* in transgenic mice. *Endocrinol* 144: 720-731, 2003.
- Patton, JG, Phillips, JA III, Ryther, RC: Targeted Degradation of RNA. United States Provisional Patent Application # 60/516,391, Nov 26, 2003.
- Williams, SM, Ritchie, MD, Phillips, JA III, Dawson, E, Prince, M, Dzhura, E, Willis, A, Semanya, A, Summar, M, White, BC, Addy, JH, Kpodonu, J, Wong, Jose, PA and Moore, JH: Multilocus analysis of hypertension: a hierarchical approach to a complex problem. *Hum Hered* 57: 28-38, 2004.
- Ryther, RCC, Flynt, AS, Harris, BD, Phillips, JA III and Patton, JG: Splicing of G1 is regulated by multiple enhancers whose mutation produces a dominant-negative GH isoform that can be degraded with allele-specific siRNA: *Endocrinology* 145: 2988-2996, 2004.
- Lawson, WE, Grant, SW, Ambrosini, V, Womble, KE, Dawson, EP, Lane, KB, Markin, C, Renzoni, E, Lympany, P, Thomas, AQ, Roldan, J, Scott, TA, Blackwell, TS, Phillips, JA III, Loyd, JE and duBois, RM: Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. *Thorax* 59:977-980, 2004.
- Steele, MP, Speer, MC, Loyd, JE, Brown, KK, Herron, A, Slifer, S, Burch, LH, Wahidi, MM, Phillips, JA III, Sporn, TA, McAdams, HP, Schwarz, MI and Schwartz, DA: The clinical and pathologic features of familial interstitial pneumonia (FIP). *Am J Resp Crit Care Med* 172:1146-1152, 2005.
- Phillips, JA III, Vnencak-Jones, C and Layman, LC: PROP1-Related Combined Pituitary Hormone Deficiency. *GeneClinics* at www.GeneClinics.org, 2005.
- Ryther, RCC, Flynt, AS, Phillips, JA III, and Patton, JG. siRNA therapeutics: big potential from small RNAs. *Gene Therapy* 12: 5-11, 2005.
- Garland, EM, Winker, R, Williams, SM, Jiang, L, Stanton, K, Byrne, DW, Biaggioni, I, Cascorbi, I, Phillips, JA III, Harris, PA, Rudiger, H and Robertson, D: Endothelial NO Synthase polymorphisms and Postural Tachycardia Syndrome. *Hypertension* 46: 1103-1110, 2005.
- Cogan, JD, Vnencak-Jones, CL, Phillips, JA III, Lane, KB, Wheeler, LA, Robbins, IM, Garrison, G, Ledges, LK and Loyd, JE: Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. *Genetics in Medicine* 7:169-174, 2005.
- Willers ED, Newman JH, Loyd JE, Robbins IM, Wheeler LA, Prince MA, Stanton KC, Cogan JA, Runo JR, Byrne D, Humbert M, Simonneau G, Sztrymf B, Morse JA, Knowles JA, Roberts KE, McElroy JJ, Barst RJ, and Phillips JA 3rd: Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 173:798-802, 2006.
- Potter, A, Phillips, JA III and Rimoin, DL: Genetic Disorders of the Pituitary Gland: In Principles and Practice of Medical Genetics, Rimoin, DL, Connor, JM, Pyeritz, RE and Korf, BR (eds), Fifth Edition, Elsevier Inc, in press, 2006.
- Agirbasli D, Agirbasli M, Williams SM, Phillips JA 3rd: Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients. *Coron Artery Dis*. 17:413-7, 2006.
- Cogan, JD, Pauciulo, MW, Batchman, AP, Prince, MA, Robbins, IM, Hedges, LK, Stanton, KC, Wheeler, LA, Phillips, JA III, Loyd, JE and Nichols, WC: High frequency of BMPR2 exonic deletions/duplications in familial arterial hypertension. *Am J Resp Crit Care Med* 174:590-8, 2006.
- Loyd, J.E. and Phillips, J.A. III: BMPR2-Related Primary Pulmonary Hypertension. *GeneClinics* available at www.GeneClinics.org, 2007.
- Armanios M, Chen J J-L, Cogan JD, Lawson W E, Alder J K, Ingersol R G, Markin C, Xie M, Cogan JD, Phillips J A III, Lansdorp P M, Greider CW and Loyd JE: Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis. *New Eng J Med* 356: 1317- 1326, 2007.

- Meyrick, BO, Friedman, DB, Billheimer, D, Cogan, JD, Prince, MA, Phillips, JA III, and Loyd, JE. Proteomics of Transformed Lymphocytes from a Family with Familial Pulmonary Arterial Hypertension. AJRCCM Articles in Press. Published 10/11/07 as doi:10.1164/rccm.200703-499OC.
- Shariat N, Ryther RCC, Phillips JA III, Robinson ICAF and Patton JG. Rescue of Pituitary Function in a Mouse Model of Isolated Growth Hormone Deficiency Type II by RNAi. Endocrinology, Published 11/15/07 as doi:10.1210/en.2007-1360.
- Newman JH, Phillips JA III, Loyd JE. Pulmonary Hypertension and the TGF- β Superfamily. Annals of Internal Medicine 148: 278-283, 2008.
- Adler, DH, Cogan, JD, Phillips, JA III, Iverson, T, Stein, JA, Brenner, DA, Morrow, JD, Boutaud, O and Oates, JA: Inherited Human cPLA2-alpha Deficiency Associated with Impaired Eicosanoid Biosynthesis, Small Intestinal Ulceration and Platelet Dysfunction. J Clin Invest First published ahead of print Mar 01, 2008 as doi: 10.1172/JCI30473.
- Phillips JA III, Poling JS, Phillips CA, Stanton KC, Austin ED, Cogan JD, Wheeler L, Yu C, Dietz HC and Loyd JE. Synergistic heterozygosity for functional *TGF β 1* SNPs and *BMP2* mutations modulates the age of diagnosis of Familial Pulmonary Arterial Hypertension (FPAH). Genetics in Medicine 10: 359-365, 2008.
- Alder JK, Chen JJ-L, Lancaster L, Danoff S, Su S-C, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, Phillips JAIII, Lansdorp PM, Loyd JE, Armanios MY. Short telomeres are a risk factor for Idiopathic Pulmonary Fibrosis. Proc Natl Acad Sci USA 105:13051-56, 2008. First pub Sept 2, 2008 as doi/10.1073/pnas.08042280105.

C. Research Support

Ongoing Research Support

- 5R01 DK35592-20 (Phillips) 04/01/2005-04/30/2010
NIH/NIDDK
GH Alternative Splicing: Mechanisms and Disease
This is a study of a new type of enhancer sequences that regulate alternative splicing of gene transcripts. The interactions between these enhancers and SR proteins to achieve regulation of normal splicing patterns is being studied to determine the underlying mechanisms that regulate alternative splicing.
- N/A (Phillips) 07/01/2008-06/30/2009
State of Tennessee
The major goals of this project seek to reduce the frequency and burden of genetic disorders in the middle Tennessee and adjoining regions by newborn screening, early diagnosis, treatment and education of affected individuals, their relatives and those at risk. Methods used include biochemical, clinical and cytogenetic and molecular studies to identify affected individuals.
- 1P01 HL072058-05 (Loyd) 08/04/2003-07/31/2009
NIH/NHLB
Genetic and Environmental Pathogenesis of PPH
Our target goals are to identify the modifying genes and environmental features that regulate the clinical expression of mutations in *BMP2*; to develop understanding about how *BMP2* mutations result in disease; and to identify the undiscovered mutations which cause PPH.
- 1 U54 RR 023499-01A1 (Bernard) 09/30/2007 - 09/29/2012
NIH/NCRR
The Vanderbilt Institute for Clinical and Translational Research (VICTR)
This program constitutes an institute which permits Vanderbilt to forge a uniquely transformative, novel, self-evaluated, integrative academic home for clinical and translational science, where both research and researchers flourish. This program will be organized and designed to focus on both bench to bedside and bedside to practice translation. Vanderbilt's institute will complement and interact with the existing NIH funded centers and industry. The program incorporates a

Completed Research Support

- 2M01 RR00095 (Balsler) 12/1/2002-11/30/2007
NIH/NCRR
General Clinical Research Center – Genetics Core
The goal of this study is to provide information about and access to current methods of genetic analysis to assist GCRC investigators in their studies.